Results 221 to 230 of about 18,195 (260)
Some of the next articles are maybe not open access.
Lansoprazole-Induced Thrombocytopenia
Annals of Pharmacotherapy, 2002OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole. CASE SUMMARY: An 85-year-old white man presented with an upper gastrointestinal hemorrhage from a gastric ulcer. His platelet count was normal on admission.
Jonathan A Zlabek +1 more
openaire +2 more sources
Lansoprazole: A Comprehensive Review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997Lansoprazole is the second member of the substituted benzimidazole class of antisecretory agents approved for use in the United States. These drugs decrease parietal cell acid secretion by inhibiting H+,K+‐adenosine triphosphatase, the final step in the secretion of acid.
Anthony E. Zimmermann, Brian G. Katona
openaire +3 more sources
Pediatric Drugs, 2003
As reported in the accompanying article, lansoprazole has been successfully used in the treatment of children with GERD. It was well tolerated, and was effective in providing symptomatic relief in several pediatric studies. Constipation, vomiting, dizziness, diarrhea, headache or insomnia may occur in 3 years’ duration) use of proton pump inhibitors ...
openaire +5 more sources
As reported in the accompanying article, lansoprazole has been successfully used in the treatment of children with GERD. It was well tolerated, and was effective in providing symptomatic relief in several pediatric studies. Constipation, vomiting, dizziness, diarrhea, headache or insomnia may occur in 3 years’ duration) use of proton pump inhibitors ...
openaire +5 more sources
Clinical Pharmacokinetics of Lansoprazole
Clinical Pharmacokinetics, 1995Lansoprazole, a benzimidazole derivative with antisecretory and antiulcer activities, inhibits the acid pump activity at the final stage of the enzyme process and therefore reduces the acid secretion of parietal cells. Lansoprazole is converted to active metabolites in the acid environment of these cells.
Flouvat B, Landes Bd, Petite Jp
openaire +3 more sources
Drugs, 2004
An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole. In healthy volunteers, oral and intravenous lansoprazole 30 mg/day were equivalent in suppressing basal and pentagastrin-stimulated maximum gastric acid output.
Toni M Dando, Greg L. Plosker
openaire +3 more sources
An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole. In healthy volunteers, oral and intravenous lansoprazole 30 mg/day were equivalent in suppressing basal and pentagastrin-stimulated maximum gastric acid output.
Toni M Dando, Greg L. Plosker
openaire +3 more sources
Pharmacokinetics of Lansoprazole in Hemodialysis Patients
The Journal of Clinical Pharmacology, 1995The pharmacokinetics of the new benzimidazole proton pump inhibitor lansoprazole and five of its metabolites were assessed after single oral dose administration to five hemodialysis patients. Patients were studied on dialysis and nondialysis days. Multiple blood and dialysate samples were collected after dosing and were assayed for lansoprazole and ...
John M. Cavanaugh +2 more
openaire +3 more sources
Collagenous Colitis Associated With Lansoprazole
Journal of Clinical Gastroenterology, 2002Collagenous colitis is a diarrheal illness of unknown cause. The purpose of this report is to describe a case of collagenous colitis related to lansoprazole exposure.Case report.A patient is described who developed clinical and pathologic findings of collagenous colitis during treatment with lansoprazole and omeprazole.
Gilbert M. Wilcox, Anthony Mattia
openaire +3 more sources
Alimentary Pharmacology & Therapeutics, 1993
SUMMARYThe care with which patients are monitored during clinical trials provides an excellent database to assess the tolerability and safety of drugs. Additional information can be obtained from knowledge of the compound itself, its metabolism and its pharmacological action.
openaire +4 more sources
SUMMARYThe care with which patients are monitored during clinical trials provides an excellent database to assess the tolerability and safety of drugs. Additional information can be obtained from knowledge of the compound itself, its metabolism and its pharmacological action.
openaire +4 more sources
Effect of Lansoprazole on Peptic Ulcers
Journal of Clinical Gastroenterology, 1995Lansoprazole is the first proton pump inhibitor developed in Japan. We studied the clinical efficacy of lansoprazole 30 mg q.d. on peptic ulcers and the subsequent relapse rates. The endoscopic healing rate of gastric ulcers (n = 86) after 8 weeks of treatment and duodenal ulcers (n = 52) after 6 weeks of treatment were 94.2 and 96.2%, respectively ...
Tanenao Eto +3 more
openaire +3 more sources